Dr. John Mascarenhas on the COMFORT-I/II Studies for Ruxolitinib in Myelofibrosis

Video

The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis.

John Mascarenhas, MD, associate professor of medicine, Mount Sinai Hospital, discusses the COMFORT-I and COMFORT-II studies. The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis. In both studies ruxolitinib reduced splenomegaly and improving symptoms, mostly by down-modulating inflammitory cytokine signaling.

Related Videos
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Expert on BPDCN
Expert on BPDCN
Related Content